MEI Pharma

MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.

Deal Dispatch

Commodities

Exclusives

Interview

AMCR

BERY

BMWYY

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

GOOG

GOOGL

KRON

MEIP

NISTF

PARA

SAVE

SBUX

SHEL

TSX:SGO

ULCC

VWAGY

Darwin Financial&#39;s Joshua Robinson talks to Benzinga about the firm&#39;s latest commodities deal, and more M&amp;A news from this past week.

Deal Dispatch: Starbucks Considers China Sale, Private Equity Bankrupts Snack Company, Darwin Financial Talks Mining

AAUKF

APTV

ATSG

FFIV

PARIS:SGO

ROIC

SLGWF

SLNG

TRIP

Evolent Health, Kronos Bio, Saint-Gobain, Shell and Unilever are on the sell-side this week. Benzinga&#39;s Deal Dispatch has the latest M&amp;A updates.

Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul

movers image

News

Intraday Update

Markets

Movers

Trading Ideas

APLD

ATPC

AVAH

CMAX

CRWD

DOGZ

EMBC

FTEL

KARO

LGCB

LPSN

MEDS

MIRA

MNSO

NCPL

NUKK

NWGL

PRTG

PSIG

RYAAY

SAVA

SERV

SLNA

SLRX

SNOA

SOPA

TELL

TKNO

VIRI

XCUR

Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

MEI Pharma Inc

Press Releases

MEI Pharma to Consider Strategic Alternatives

MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives

MEI Pharma Reports Fiscal Year End 2024 Cash Position

MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position

MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position

The Radoff-JEC Group Nominates Three Highly Qualified Candidates for Election to the Atea Pharmaceuticals Board of Directors

ABBV

AVIR

CARM

COYA

RIBT

SYBX

TSX:PHO

Abpro Hldgs

Allarity Therapeutics, Inc. - Common stock

Allarity Therapeutics

BioVie

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Can-Fite Biopharma Ltd Sponsored ADR (Israel)

Can Fite Biofarma

Calidi Biotherapeutics, Inc. Common Stock

Calidi Biotherapeutics

Elevation Oncology

Equillium

Ernexa Therapeutics

GlycoMimetics

Geovax Labs

HCW Biologics

iBio

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Leap Therapeutics

Moleculin Biotech

MetaVia

NextCure

Passage Bio

BiomX

Portage Biotech

Rallybio

SAB Biotherapeutics

Unity Biotechnology

X4 Pharmaceuticals

Stifel

Brookline Capital

HC Wainwright & Co.

Jefferies

Comments

MEI Pharma

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell